In a meeting with the Cuban President Miguel Díaz-Canel, the specialists enlightened the encouraging results on improvements in cognitive impairment rate.
According to the experts, in 27 years of experience treating patients suffering from Alzheimer’s they have never seen people showing positive progress.
NeuroEPO´s developers said that registering this neuroprotective drug, Cuba would gain sovereignty in treating Alzheimer’s disease and would also achieve a scientific milestone that other nations have not reached.
This project –carried out by the Center for Molecular Immunology (CIM, in Spanish), the Center for Research and Development of Medicines and other institutions- consisted of developing a novel recombinant human erythropoietin (NeuroEpo) formula, with characteristics similar to that produced by the brain.
Recently, the CIM Clinical Research Director Tania Crombet explained that NeuroEpo is a nasal drug, very comfortable and easy to use.